Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in Chinese Subjects With Moderately to Severely Active Ulcerative Colitis
NCT03221036Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Aug 2017
- Primary completion
- Sep 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in ulcerative colitis (UC) (4 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants with Clinical Response at 10 weeks and Percentage of Participants with Clinical Remission at 60 weeks. Started Aug 2017; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03221036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221036.